Pacific Health Care Organization, Inc.

OTCPK:PFHO Stock Report

Market Cap: US$10.5m

Pacific Health Care Organization Valuation

Is PFHO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFHO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PFHO ($0.82) is trading below our estimate of fair value ($2.04)

Significantly Below Fair Value: PFHO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFHO?

Key metric: As PFHO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PFHO. This is calculated by dividing PFHO's market cap by their current earnings.
What is PFHO's PE Ratio?
PE Ratio12.1x
EarningsUS$869.09k
Market CapUS$10.50m

Price to Earnings Ratio vs Peers

How does PFHO's PE Ratio compare to its peers?

The above table shows the PE ratio for PFHO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.9x
NEUE NeueHealth
1.5xn/aUS$40.9m
NIVF NewGenIvf Group
42.3xn/aUS$6.0m
IDXG Interpace Biosciences
2.4xn/aUS$11.8m
AMS American Shared Hospital Services
5.2xn/aUS$19.4m
PFHO Pacific Health Care Organization
12.1xn/aUS$10.5m

Price-To-Earnings vs Peers: PFHO is good value based on its Price-To-Earnings Ratio (12.1x) compared to the peer average (13.8x).

Price to Earnings Ratio vs Industry

How does PFHO's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.5xn/aUS$40.85m
IDXG Interpace Biosciences
2.4xn/aUS$11.79m
FZMD Fuse Medical
1.4xn/aUS$4.22m
No more companies available in this PE range
PFHO 12.1xIndustry Avg. 25.4xNo. of Companies12PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PFHO is good value based on its Price-To-Earnings Ratio (12.1x) compared to the US Healthcare industry average (25.8x).

Price to Earnings Ratio vs Fair Ratio

What is PFHO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFHO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PFHO's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$92.2b

Operates as a health benefits company in the United States.

ELV

US$403.60

7D

-0.8%

1Y

-15.9%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

7D

2.8%

1Y

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

7D

-27.1%

1Y

80.4%